Last updated: 2026-02-24 05:19:03 ET
The Trump administration appears to be gearing up for a substantial response to Iran, Washington state allegedly spends millions on gender surgeries f...
The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the company's application to market...
With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.
The United States Food and Drug Administration has decided to review a new vaccine for influenza, despite rejecting the application earlier this month...
Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to rejec...
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal inf...
In February 2026, Moderna reported full-year 2025 revenue of US$1.94 billion and a net loss of US$2.82 billion, while the FDA’s vaccines ...
Moderna’s stock was surging after the FDA said it would review the biotech’s flu-vaccine candidate, a week after it had refused to do so.
